In recent years, the rise in intestinal disease has driven the hunt for safer, cost-effective alternatives to traditional, side-effect-laden medications. Litchi polysaccharide (LP), derived from litchi pulp, has emerged as a potential intestinal protector, but its efficacy has not been well-established. Our study have demonstrated LP significantly preserves the integrity of the intestinal barrier in both Caenorhabditis elegans model and antibiotic-exposed mice. Furthermore, LP regulates the gut microbiota, promoting the dominance of beneficial bacteria such as Anaerostipes and Lachnoclostridium in antibiotic-exposed mice and elevating the levels of short-chain fatty acids (SCFAs). LP2-a, a key component making up 11.13 % of LP and with a molecular weight of 72,477 Da, has been isolated and identified as the main active agent. Its molecular structure, featuring galactose and arabinose and possessing a main chain composed of specific sugar units and side chains, is crucial for its protective effects. In C. elegans, LP2-a regulates the expression of intestinal structure-related genes, including up-regulating the expression of act-5 and down-regulating the levels of ajm-1, erm-1, and zoo-1, protecting the integrity of the intestinal barrier. This study provides a theoretical foundation for the potential use of LP, particularly LP2-a, in the treatment of intestinal diseases.
Keywords: Intestinal inflammatory injury; Litchi polysaccharide; Separation and purification; Structural characterization.
Copyright © 2025 Elsevier B.V. All rights reserved.